» Articles » PMID: 37834411

Epigenetic Modulators As Therapeutic Agents in Cancer

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Oct 14
PMID 37834411
Authors
Affiliations
Soon will be listed here.
Abstract

Epigenetics play a crucial role in gene regulation and cellular processes. Most importantly, its dysregulation can contribute to the development of tumors. Epigenetic modifications, such as DNA methylation and histone acetylation, are reversible processes that can be utilized as targets for therapeutic intervention. DNA methylation inhibitors disrupt DNA methylation patterns by inhibiting DNA methyltransferases. Such inhibitors can restore normal gene expression patterns, and they can be effective against various forms of cancer. Histone deacetylase inhibitors increase histone acetylation levels, leading to altered gene expressions. Like DNA methylation inhibitors, histone methyltransferase inhibitors target molecules involved in histone methylation. Bromodomain and extra-terminal domain inhibitors target proteins involved in gene expression. They can be effective by inhibiting oncogene expression and inducing anti-proliferative effects seen in cancer. Understanding epigenetic modifications and utilizing epigenetic inhibitors will offer new possibilities for cancer research.

Citing Articles

Oxidative-Stress-Mediated Epigenetic Dysregulation in Spermatogenesis: Implications for Male Infertility and Offspring Health.

Kaltsas A, Markou E, Kyrgiafini M, Zikopoulos A, Symeonidis E, Dimitriadis F Genes (Basel). 2025; 16(1).

PMID: 39858640 PMC: 11765119. DOI: 10.3390/genes16010093.


Knockdown of Methylation-Related Gene MBD2 Blocks Cell Growth by Upregulating p21 Expression in Head and Neck Squamous Cell Carcinoma.

Cao T, Shen X, Pei F, Jiang T, Zhang J, Zhou H Cancer Rep (Hoboken). 2024; 7(12):e70080.

PMID: 39676597 PMC: 11647173. DOI: 10.1002/cnr2.70080.


Hypoxia and aging: molecular mechanisms, diseases, and therapeutic targets.

Nisar A, Khan S, Li W, Hu L, Samarawickrama P, Gold N MedComm (2020). 2024; 5(11):e786.

PMID: 39415849 PMC: 11480526. DOI: 10.1002/mco2.786.


Deciphering Depression: Epigenetic Mechanisms and Treatment Strategies.

Aljabali A, Alkaraki A, Gammoh O, Tambuwala M, Mishra V, Mishra Y Biology (Basel). 2024; 13(8).

PMID: 39194576 PMC: 11351889. DOI: 10.3390/biology13080638.


GLP and G9a histone methyltransferases as potential therapeutic targets for lymphoid neoplasms.

Silva-Carvalho A, Filiu-Braga L, Bogea G, de Assis A, Pittella-Silva F, Saldanha-Araujo F Cancer Cell Int. 2024; 24(1):243.

PMID: 38997742 PMC: 11249034. DOI: 10.1186/s12935-024-03441-y.


References
1.
Zheng A, Bilbao M, Sookram J, Linden K, Morgan A, Ostrovsky O . Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells. Cancer Biol Ther. 2022; 23(1):254-264. PMC: 8993057. DOI: 10.1080/15384047.2022.2052540. View

2.
Gravina G, Festuccia C, Marampon F, Popov V, Pestell R, Zani B . Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer. 2010; 9:305. PMC: 3001713. DOI: 10.1186/1476-4598-9-305. View

3.
Dillon S, Zhang X, Trievel R, Cheng X . The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol. 2005; 6(8):227. PMC: 1273623. DOI: 10.1186/gb-2005-6-8-227. View

4.
French C . NUT midline carcinoma. Cancer Genet Cytogenet. 2010; 203(1):16-20. PMC: 3000636. DOI: 10.1016/j.cancergencyto.2010.06.007. View

5.
Shorstova T, Foulkes W, Witcher M . Achieving clinical success with BET inhibitors as anti-cancer agents. Br J Cancer. 2021; 124(9):1478-1490. PMC: 8076232. DOI: 10.1038/s41416-021-01321-0. View